Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
29.03.2018 12:30:00

TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

JACKSONVILLE, Fla., March 29, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that the Company will host a conference call and live audio webcast on Thursday, April 5, 2018, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2017.

Reserve Your Seat: Register Today
The event will be webcast live via the Internet on:

April 5, 2018
4:30 PM ET

Click here to register today, or visit https://tapimmune.com/register

Day-of Call-in Information:
To access the live conference call on April 5, 2018, at 4:30pm ET you may use:

  • (855) 238-2333 (U.S.)
  • (412) 317-5215 (International)

To access the live audio webcast, visit the Events section of the TapImmune website: http://tapimmune.com/events. The webcast will also be archived for 90 days beginning at approximately 6:30 p.m. ET, on April 5, 2018.

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be used without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.

For additional information visit: https://tapimmune.com/

To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/

 

TapImmune, Inc. logo

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-provide-fourth-quarter-and-full-year-2017-business-update-conference-call-and-webcast-300621358.html

SOURCE TapImmune Inc.

Nachrichten zu TapImmune Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu TapImmune Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!